EICHORPublic-registry site landscape for NCT07752407, “A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks”, a Symptomatic Non-erosive Gastroesophageal Reflux Disease study sponsored by Phathom Pharmaceuticals, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07752407 (registry record) |
| Study title | A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks |
| Official title | A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks |
| Sponsor | Phathom Pharmaceuticals, Inc. |
| Condition(s) | Symptomatic Non-erosive Gastroesophageal Reflux Disease |
| Phase | PHASE3 |
| Listed sites | 0 |
| Intervention(s) | Vonoprazan, Placebo |
Patient-friendly overview of this study: eichor.com/study/NCT07752407.
Eichor generates a preliminary site-risk snapshot for NCT07752407 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
